Adze-1.17.C.4

Adze-1.17.C.4 is a preclinical-stage therapeutic candidate developed by Adze Biotechnology for the treatment of various solid tumors, including melanoma, non-small cell lung cancer, and pancreatic cancer. It is part of the broader Adze-1.17 oncolytic immunotherapy platform, which utilizes systemically deliverable and conditionally replicative oncolytic viruses designed to deliver immunotherapy payloads directly into tumors. The platform aims to stimulate robust anti-tumor immune responses through both systemic and intra-tumoral administration. While specific mechanistic details for Adze-1.17.C.4 are not disclosed in public sources, related candidates from this platform (such as Adze-1.17-CD40L) function by delivering recombinant human CD40 ligand locally into solid tumors to enhance immune activation against cancer cells.